Information
References
Contents
Academic Editor
- Jaume Sastre-Garriga
Download
[1]Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Sub-cellular Biochemistry. 2012; 65: 389–455. https://doi.org/10.1007/978-94-007-5416-4_16.
[2]Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 2020; 91: 795–808. https://doi.org/10.1136/jnnp-2019-322338.
[3]Clarke CE. Parkinson’s disease. BMJ (Clinical Research Ed.). 2007; 335: 441–445. https://doi.org/10.1136/bmj.39289.437454.AD.
[4]Davie CA. A review of Parkinson’s disease. British Medical Bulletin. 2008; 86: 109–127. https://doi.org/10.1093/bmb/ldn013.
[5]Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion. 2018; 34: 2063–2073. https://doi.org/10.1080/03007995.2018.1502165.
[6]Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: Consensus from an international survey and discussion program. Parkinsonism & Related Disorders. 2015; 21: 1133–1144. https://doi.org/10.1016/j.parkreldis.2015.07.020.
[7]Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson’s Disease. 2017; 2017: 4047392. https://doi.org/10.1155/2017/4047392.
[8]Das S, Matias CM, Ramesh S, Velagapudi L, Barbera JP, Katz S, et al. Capturing Initial Understanding and Impressions of Surgical Therapy for Parkinson’s Disease. Frontiers in Neurology. 2021; 12: 605959. https://doi.org/10.3389/fneur.2021.605959.
[9]Henriksen T, Dalhoff KP, Hansen HE, Brenneche AW, Lønberg US, Danielsen EH. Access and Use of Device-Aided Therapies for Parkinson’s Disease in Denmark. Movement Disorders Clinical Practice. 2020; 7: 656–663. https://doi.org/10.1002/mdc3.12988.
[10]Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? Journal of Parkinson’s Disease. 2020; 10: S65–S73. https://doi.org/10.3233/JPD-202104.
[11]Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, et al. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson’s disease: I. Invasive therapies. European Journal of Neurology. 2022; 29: 2580–2595. https://doi.org/10.1111/ene.15386.
[12]Vivancos-Matellano F, Garcia-Ruiz AJ, Garcia-Agua Soler N. Pharmacoeconomic study of the treatment of advanced Parkinson’s disease. Revista De Neurologia. 2016; 63: 529–536.
[13]Postma MJ, Boersma C. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson’s disease. Expert Review of Clinical Pharmacology. 2012; 5: 1–4. https://doi.org/10.1586/ecp.11.69.
[14]Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology and Therapy. 2023; 12: 1937–1958. https://doi.org/10.1007/s40120-023-00533-1.
[15]Cox E, Wade R, Hodgson R, Fulbright H, Phung TH, Meader N, et al. Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2024; 28: 1–187. https://doi.org/10.3310/YDSL3294.
[16]Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson’s disease: clinical characteristics and treatment (part 1). Neurologia (Barcelona, Spain). 2013; 28: 503–521. https://doi.org/10.1016/j.nrl.2013.05.001.
[17]Valldeoriola F, Puig-Junoy J, Puig-Peiró R, Workgroup of the SCOPE study. Cost analysis of the treatments for patients with advanced Parkinson’s disease: SCOPE study (eStudio COstes Parkinson Enfermedad). Journal of Medical Economics. 2013; 16: 191–201. https://doi.org/10.3111/13696998.2012.737392.
[18]Instituto Nacional de Estadística. Índice de Precios de Consumo. Medias anuales. Índices nacionales: general y de grupos ECOICOP. Disponible en: https://www.ine.es/jaxiT3/Tabla.htm?t=50934&L=0 (Accedido: 9 Octubre 2024).
[19]Precios públicos sanitarios. Junta de Andalucía. 2018. Disponible en: https://www.juntadeandalucia.es/datosabiertos/portal/dataset/precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa/resource/8b3db748-92fc-41c0-9688-44456fa8bae4 (Accedido: 4 Octubre 2024).
[20]Precios públicos de servicios sanitarios prestados en Sistema Sanitario Público Andaluz. 2018. Disponible en: https://datos.gob.es/es/catalogo/a01002820-precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa (Accedido: 4 Octubre 2024).
[21]Burkard T, López-Güell K, Gorbachev A, Bellas L, Jödicke AM, Burn E, et al. Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model. Pharmacoepidemiology and Drug Safety. 2024; 33: e5809. https://doi.org/10.1002/pds.5809.
[22]Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. The Lancet. Neurology. 2014; 13: 141–149. https://doi.org/10.1016/S1474-4422(13)70293-X.
[23]Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders: Official Journal of the Movement Disorder Society. 2015; 30: 500–509. https://doi.org/10.1002/mds.26123.
[24]Lecigon (entacapone, carbidopa (monohydrate), levodopa). Public Assessment Report Scientific discussion. 2018. Disponible en: https://docetp.mpa.se/LMF/Lecigon%20intestinal%20gel%20ENG%20PAR_09001bee813fbfeb.pdf (Accedido: 7 Octubre 2024).
[25]Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: A randomized crossover study. Movement Disorders: Official Journal of the Movement Disorder Society. 2017; 32: 283–286. https://doi.org/10.1002/mds.26855.
[26]Szatmári S, Szász JA, Orbán-Kis K, Baróti B, Bataga S, Ciorba M, et al. Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience. Pharmaceutics. 2024; 16: 453. https://doi.org/10.3390/pharmaceutics16040453.
[27]Chaudhuri KR, Kovács N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson’s Disease. 2023; 13: 769–783. https://doi.org/10.3233/JPD-225105.
[28]Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, et al. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review. Advances in Therapy. 2021; 38: 2854–2890. https://doi.org/10.1007/s12325-021-01747-1.
[29]Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance. Clinical Parkinsonism & Related Disorders. 2024; 10: 100239. https://doi.org/10.1016/j.prdoa.2024.100239.
[30]Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M. Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods. Neurology and Therapy. 2023; 12: 1033–1049. https://doi.org/10.1007/s40120-023-00486-5.
[31]Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson’s Disease: A Mini-Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice. 2024; 11: 1188–1194. https://doi.org/10.1002/mdc3.14161.
[32]Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurology and Therapy. 2024; 13: 1055–1068. https://doi.org/10.1007/s40120-024-00635-4.
[33]Rosebraugh M, Stodtmann S, Liu W, Facheris MF. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism & Related Disorders. 2022; 97: 68–72. https://doi.org/10.1016/j.parkreldis.2022.03.012.
[34]Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology. 2018; 17: 749–759. https://doi.org/10.1016/S1474-4422(18)30239-4.
[35]Walter E, Said M. Cost-effectiveness of apomorphine in the treatment of advance Parkinson disease in the UK and Germany: results from a multicounty decision analytic model. Value in Health. 2013; 16: A622.
[36]Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. Journal of Medical Economics. 2011; 14: 584–593. https://doi.org/10.3111/13696998.2011.598201.
[37]Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease. Revue Neurologique. 1990; 146: 116–122.
[38]Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. The New England Journal of Medicine. 2006; 355: 896–908. https://doi.org/10.1056/NEJMoa060281.
[39]Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology. 2001; 57: 663–671. https://doi.org/10.1212/wnl.57.4.663.
[40]García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Movement Disorders: Official Journal of the Movement Disorder Society. 2008; 23: 1130–1136. https://doi.org/10.1002/mds.22063.
[41]Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2000; 9: 819–827. https://doi.org/10.1023/a:1008903126315.
[42]García-Ramos R, López Valdés E, Ballesteros L, Jesús S, Mir P. The social impact of Parkinson’s disease in Spain: Report by the Spanish Foundation for the Brain. Neurologia (Barcelona, Spain). 2016; 31: 401–413. https://doi.org/10.1016/j.nrl.2013.04.008.
[43]Martinez-Martín P, Rodriguez-Blazquez C, Paz S, Forjaz MJ, Frades-Payo B, Cubo E, et al. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PloS One. 2015; 10: e0145310. https://doi.org/10.1371/journal.pone.0145310.
[44]Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-Shahed J, Metz S, et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson’s disease continuum: Revelations from the MANAGE-PD validation cohort. Parkinsonism & Related Disorders. 2023; 116: 105514. https://doi.org/10.1016/j.parkreldis.2023.105514.
[45]Gomez-Inhiesto E, Acaiturri-Ayesta MT, Ustarroz-Aguirre I, Camahuali D, Urtaran-Laresgoiti M, Basabe-Aldecoa M, et al. Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies. Parkinson’s Disease. 2020; 2020: 9106026. https://doi.org/10.1155/2020/9106026.
[46]Zhao YJ, Tan LCS, Au WL, Heng DMK, Soh IAL, Li SC, et al. Estimating the lifetime economic burden of Parkinson’s disease in Singapore. European Journal of Neurology. 2013; 20: 368–374. https://doi.org/10.1111/j.1468-1331.2012.03868.x.
[47]von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, et al. Costs of illness and care in Parkinson’s disease: an evaluation in six countries. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology. 2011; 21: 180–191. https://doi.org/10.1016/j.euroneuro.2010.08.002.
[48]Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Economics. 2018; 27: 746–761. https://doi.org/10.1002/hec.3633.
[49]Sacristán JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. What is an efficient health intervention in Spain in 2020? Gaceta Sanitaria. 2020; 34: 189–193. https://doi.org/10.1016/j.gaceta.2019.06.007.
[50]Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. Journal of Medical Economics. 2019; 22: 215–225. https://doi.org/10.1080/13696998.2018.1553179.
Academic Editor
- Jaume Sastre-Garriga
Article Metrics
Download
- Contents
Information
Download
Contents
, Lucía García Trujillo 3, Antonio J García-Ruiz 1,21 Economía de la Salud y Uso Racional de Medicamentos, Departamento de Farmacología, Facultad de Medicina, 29010 Málaga, España
2 Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29016 Málaga, España
3 Servicio de Neurología, Hospital Regional Universitario de Málaga, 29010 Málaga, España
Abstract
As Parkinson’s disease progresses, symptoms develop that make it more difficult to control, either because of the presence of fluctuations despite adequate oral treatment, or because of the adverse effects caused by the continued use of levodopa, considered the gold standard. At this point in the course of the disease, there are different therapeutic alternatives that provide more continuous dopaminergic stimulation and help to improve this symptomatology: deep brain stimulation (Medtronic®: Percept™ Primary Cell (PC), Percept™ ReChargable (RC)), intestinal gel Levodopa/Carbidopa (Duodopa®) o Levodopa/Carbidopa/Entacapona (Lecigon®), as well as subcutaneous infusion of foslevodopa/foscarbidopa (Foslevodopa®) and continuous infusion of apomorphine (Dacepton®, Apo-Go®).
Pharmacoeconomic study of the different therapies for treating advanced Parkinson’s disease in Spain.
Based on a Markov model, the efficacy and costs of these therapies were compared, measuring life years gained (LYG) and quality-adjusted life years (QALY).
Dacepton® (apomorphine) is the most cost-effective option with a cost of 20,782€/QALY (1€ = 1.0815 USD, 2025), compared to three times or more for the other therapies with Lecigon® (levodopa/carbidopa/entacapone) being the least cost-effective with a cost of 104,000€/QALY. Deep brain stimulation (DBS) and Duodopa® also proved to be effective options, but more costly than Dacepton®.
These results provide additional information on the efficiency of treatments that should inform decision-making in the management of advanced Parkinson’s disease, thus enabling better resource management.
Keywords
- cost-benefit analysis
- Parkinson disease
- quality-adjusted life years
References
- [1]
Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Sub-cellular Biochemistry. 2012; 65: 389–455. https://doi.org/10.1007/978-94-007-5416-4_16. - [2]
Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 2020; 91: 795–808. https://doi.org/10.1136/jnnp-2019-322338. - [3]
Clarke CE. Parkinson’s disease. BMJ (Clinical Research Ed.). 2007; 335: 441–445. https://doi.org/10.1136/bmj.39289.437454.AD. - [4]
Davie CA. A review of Parkinson’s disease. British Medical Bulletin. 2008; 86: 109–127. https://doi.org/10.1093/bmb/ldn013. - [5]
Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion. 2018; 34: 2063–2073. https://doi.org/10.1080/03007995.2018.1502165. - [6]
Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: Consensus from an international survey and discussion program. Parkinsonism & Related Disorders. 2015; 21: 1133–1144. https://doi.org/10.1016/j.parkreldis.2015.07.020. Cited within: 1Google Scholar - [7]
Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson’s Disease. 2017; 2017: 4047392. https://doi.org/10.1155/2017/4047392. - [8]
Das S, Matias CM, Ramesh S, Velagapudi L, Barbera JP, Katz S, et al. Capturing Initial Understanding and Impressions of Surgical Therapy for Parkinson’s Disease. Frontiers in Neurology. 2021; 12: 605959. https://doi.org/10.3389/fneur.2021.605959. - [9]
Henriksen T, Dalhoff KP, Hansen HE, Brenneche AW, Lønberg US, Danielsen EH. Access and Use of Device-Aided Therapies for Parkinson’s Disease in Denmark. Movement Disorders Clinical Practice. 2020; 7: 656–663. https://doi.org/10.1002/mdc3.12988. - [10]
Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? Journal of Parkinson’s Disease. 2020; 10: S65–S73. https://doi.org/10.3233/JPD-202104. - [11]
Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, et al. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson’s disease: I. Invasive therapies. European Journal of Neurology. 2022; 29: 2580–2595. https://doi.org/10.1111/ene.15386. - [12]
Vivancos-Matellano F, Garcia-Ruiz AJ, Garcia-Agua Soler N. Pharmacoeconomic study of the treatment of advanced Parkinson’s disease. Revista De Neurologia. 2016; 63: 529–536. - [13]
Postma MJ, Boersma C. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson’s disease. Expert Review of Clinical Pharmacology. 2012; 5: 1–4. https://doi.org/10.1586/ecp.11.69. - [14]
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology and Therapy. 2023; 12: 1937–1958. https://doi.org/10.1007/s40120-023-00533-1. - [15]
Cox E, Wade R, Hodgson R, Fulbright H, Phung TH, Meader N, et al. Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2024; 28: 1–187. https://doi.org/10.3310/YDSL3294. - [16]
Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson’s disease: clinical characteristics and treatment (part 1). Neurologia (Barcelona, Spain). 2013; 28: 503–521. https://doi.org/10.1016/j.nrl.2013.05.001. - [17]
Valldeoriola F, Puig-Junoy J, Puig-Peiró R, Workgroup of the SCOPE study. Cost analysis of the treatments for patients with advanced Parkinson’s disease: SCOPE study (eStudio COstes Parkinson Enfermedad). Journal of Medical Economics. 2013; 16: 191–201. https://doi.org/10.3111/13696998.2012.737392. - [18]
Instituto Nacional de Estadística. Índice de Precios de Consumo. Medias anuales. Índices nacionales: general y de grupos ECOICOP. Disponible en: https://www.ine.es/jaxiT3/Tabla.htm?t=50934&L=0 (Accedido: 9 Octubre 2024). Cited within: 1Google Scholar - [19]
Precios públicos sanitarios. Junta de Andalucía. 2018. Disponible en: https://www.juntadeandalucia.es/datosabiertos/portal/dataset/precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa/resource/8b3db748-92fc-41c0-9688-44456fa8bae4 (Accedido: 4 Octubre 2024). - [20]
Precios públicos de servicios sanitarios prestados en Sistema Sanitario Público Andaluz. 2018. Disponible en: https://datos.gob.es/es/catalogo/a01002820-precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa (Accedido: 4 Octubre 2024). - [21]
Burkard T, López-Güell K, Gorbachev A, Bellas L, Jödicke AM, Burn E, et al. Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model. Pharmacoepidemiology and Drug Safety. 2024; 33: e5809. https://doi.org/10.1002/pds.5809. - [22]
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. The Lancet. Neurology. 2014; 13: 141–149. https://doi.org/10.1016/S1474-4422(13)70293-X. - [23]
Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders: Official Journal of the Movement Disorder Society. 2015; 30: 500–509. https://doi.org/10.1002/mds.26123. - [24]
Lecigon (entacapone, carbidopa (monohydrate), levodopa). Public Assessment Report Scientific discussion. 2018. Disponible en: https://docetp.mpa.se/LMF/Lecigon%20intestinal%20gel%20ENG%20PAR_09001bee813fbfeb.pdf (Accedido: 7 Octubre 2024). - [25]
Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: A randomized crossover study. Movement Disorders: Official Journal of the Movement Disorder Society. 2017; 32: 283–286. https://doi.org/10.1002/mds.26855. - [26]
Szatmári S, Szász JA, Orbán-Kis K, Baróti B, Bataga S, Ciorba M, et al. Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience. Pharmaceutics. 2024; 16: 453. https://doi.org/10.3390/pharmaceutics16040453. - [27]
Chaudhuri KR, Kovács N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson’s Disease. 2023; 13: 769–783. https://doi.org/10.3233/JPD-225105. - [28]
Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, et al. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review. Advances in Therapy. 2021; 38: 2854–2890. https://doi.org/10.1007/s12325-021-01747-1. - [29]
Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance. Clinical Parkinsonism & Related Disorders. 2024; 10: 100239. https://doi.org/10.1016/j.prdoa.2024.100239. Cited within: 3Google Scholar - [30]
Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M. Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods. Neurology and Therapy. 2023; 12: 1033–1049. https://doi.org/10.1007/s40120-023-00486-5. - [31]
Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson’s Disease: A Mini-Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice. 2024; 11: 1188–1194. https://doi.org/10.1002/mdc3.14161. - [32]
Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurology and Therapy. 2024; 13: 1055–1068. https://doi.org/10.1007/s40120-024-00635-4. - [33]
Rosebraugh M, Stodtmann S, Liu W, Facheris MF. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism & Related Disorders. 2022; 97: 68–72. https://doi.org/10.1016/j.parkreldis.2022.03.012. Cited within: 2Google Scholar - [34]
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology. 2018; 17: 749–759. https://doi.org/10.1016/S1474-4422(18)30239-4. - [35]
Walter E, Said M. Cost-effectiveness of apomorphine in the treatment of advance Parkinson disease in the UK and Germany: results from a multicounty decision analytic model. Value in Health. 2013; 16: A622. - [36]
Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. Journal of Medical Economics. 2011; 14: 584–593. https://doi.org/10.3111/13696998.2011.598201. - [37]
Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease. Revue Neurologique. 1990; 146: 116–122. - [38]
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. The New England Journal of Medicine. 2006; 355: 896–908. https://doi.org/10.1056/NEJMoa060281. - [39]
Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology. 2001; 57: 663–671. https://doi.org/10.1212/wnl.57.4.663. - [40]
García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Movement Disorders: Official Journal of the Movement Disorder Society. 2008; 23: 1130–1136. https://doi.org/10.1002/mds.22063. - [41]
Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2000; 9: 819–827. https://doi.org/10.1023/a:1008903126315. - [42]
García-Ramos R, López Valdés E, Ballesteros L, Jesús S, Mir P. The social impact of Parkinson’s disease in Spain: Report by the Spanish Foundation for the Brain. Neurologia (Barcelona, Spain). 2016; 31: 401–413. https://doi.org/10.1016/j.nrl.2013.04.008. - [43]
Martinez-Martín P, Rodriguez-Blazquez C, Paz S, Forjaz MJ, Frades-Payo B, Cubo E, et al. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PloS One. 2015; 10: e0145310. https://doi.org/10.1371/journal.pone.0145310. - [44]
Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-Shahed J, Metz S, et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson’s disease continuum: Revelations from the MANAGE-PD validation cohort. Parkinsonism & Related Disorders. 2023; 116: 105514. https://doi.org/10.1016/j.parkreldis.2023.105514. Cited within: 1Google Scholar - [45]
Gomez-Inhiesto E, Acaiturri-Ayesta MT, Ustarroz-Aguirre I, Camahuali D, Urtaran-Laresgoiti M, Basabe-Aldecoa M, et al. Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies. Parkinson’s Disease. 2020; 2020: 9106026. https://doi.org/10.1155/2020/9106026. - [46]
Zhao YJ, Tan LCS, Au WL, Heng DMK, Soh IAL, Li SC, et al. Estimating the lifetime economic burden of Parkinson’s disease in Singapore. European Journal of Neurology. 2013; 20: 368–374. https://doi.org/10.1111/j.1468-1331.2012.03868.x. - [47]
von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, et al. Costs of illness and care in Parkinson’s disease: an evaluation in six countries. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology. 2011; 21: 180–191. https://doi.org/10.1016/j.euroneuro.2010.08.002. - [48]
Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Economics. 2018; 27: 746–761. https://doi.org/10.1002/hec.3633. - [49]
Sacristán JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. What is an efficient health intervention in Spain in 2020? Gaceta Sanitaria. 2020; 34: 189–193. https://doi.org/10.1016/j.gaceta.2019.06.007. - [50]
Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. Journal of Medical Economics. 2019; 22: 215–225. https://doi.org/10.1080/13696998.2018.1553179.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.